Radiology AI Directory

FDA-cleared profile

Fibresolve (with PCCP)

Imvaria, Inc.

Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

CT/CTA workflow
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.

Product overview

Start with the essentials

Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Overview status: Source-reviewed overview

Clinical takeaway

Clinical role: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Evidence takeaway

Evidence from the reviewed source record: K252041 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for Fibresolve with PCCP. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.

Clinical details

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Clinicians qualified in care of lung disease, including clinicians caring for patients with interstitial lung disease.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Care setting and population
Interstitial-lung-disease referral and multidisciplinary discussion workflows.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Adjunct lung-CT classification and referral support before invasive testing.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM-compliant lung CT studies from patients aged over 22 years with pulmonary symptoms.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Output and human action
A report containing patient and technical information and a binary result suggesting the classified disease pattern.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that Fibresolve is adjunctive, must be used with history, symptoms, other tests, and professional judgment, and is not a replacement for multidisciplinary or invasive evaluation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252041
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Lungs and interstitial lung disease patterns
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-11-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA package describes lung CT DICOM input, a cloud image receiver API, image ingestion and analysis, and output through an API to a hospital or clinic workflow.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Deployment and data flow
The FDA package describes cloud software and API integration or manual manufacturer submission; current hosting, security, availability, retention, and contractual boundaries remain unknown.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Security and privacy
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Use by clinicians qualified in care of lung disease, including clinicians caring for patients with interstitial lung disease. Follow the exact labeling, local training, supervision, and escalation requirements.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring and change control
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K252041.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K252041.

exact submission · checked 2026-09-04
Source

Deployment boundary

The FDA package describes cloud software and API integration or manual manufacturer submission; current hosting, security, availability, retention, and contractual boundaries remain unknown.

exact submission · checked 2026-09-04
Source

Interoperability acceptance

The FDA package describes lung CT DICOM input, a cloud image receiver API, image ingestion and analysis, and output through an API to a hospital or clinic workflow.

exact submission · checked 2026-09-04
Source

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K252041.

exact submission · checked 2026-09-04
Source

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04
Source

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
SourceSource

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K252041 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for Fibresolve with PCCP. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252041 FDA evidence package for Fibresolve (with PCCP)

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationLungs and interstitial lung disease patterns
  • Scopeexact submission
  • Tested versionFibresolve with PCCP
  • IndependenceSponsor or vendor study

K252041

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Source

Costs and setup

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No public list price or commercial contract for the exact submission and version was identified.

Reimbursement and coding
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

Source

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K252041 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
8Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. The records name Fibresolve but do not identify the K252041 with-PCCP configuration or tested build; PMID 42587682 identifies an FDA-authorized product through the earlier DEN220040 record rather than K252041. The current discovery snapshot contains 8 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources & history

How this profile was documented

Open the ledger for source dates, scope, and research-record updates.

View source ledger and history

Source ledger

  1. FDA 510(k) decision material K252041: Fibresolve (with PCCP)

    U.S. Food and Drug Administration - Published 2025-11-07 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Fibresolve (with PCCP) model card (K252041)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K252041 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253560

Enhanced Boundary for PCCT

Ge Medical Systems, LLC

Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.

Modality
CT/CTA
Anatomy
Head
Decision
2026-06-24
CT/CTA workflow
FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and...

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
CT/CTA workflow
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
CT/CTA workflow
FDA-cleared K250290

SurgiTwin

Twinsight

SurgiTwin is a web pre-surgical knee-planning system that uses patient CT images to provide two-dimensional and three-dimensional planning information and a PDF report for adults...

Modality
CT/CTA
Anatomy
Knee
Decision
2025-08-29
CT/CTA workflow